{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:51:11Z","timestamp":1793731871642,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eururo.2023.10.012","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T17:25:17Z","timestamp":1699377917000},"page":"125-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0827","authenticated-orcid":false,"given":"Marcin","family":"Miszczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Nowicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Ryul","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G\u00f3mez","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Goldner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.10.012_b0005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euf.2022.10.013","article-title":"Surgical metastasectomy for visceral and bone prostate cancer metastases: a mini-review","volume":"9","author":"Rajwa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.10.012_b0010","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0020","unstructured":"EAU. EAU guidelines. Presented at the EAU Annual Congress Milan 2023. 2023."},{"key":"10.1016\/j.eururo.2023.10.012_b0025","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.10.012_b0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.10.012_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.10.012_b0040","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.10.012_b0045","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.10.012_b0050","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2023.10.012_b0055","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2023.10.012_b0065","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2023.10.012_b0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2018.03.021","article-title":"Will image-guided metastasis-directed therapy change the treatment paradigm of oligorecurrent prostate cancer?","volume":"74","author":"Giannarini","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.10.012_b0075","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0080","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2023.10.012_b0085","first-page":"61","article-title":"Statistical data extraction and validation from graph for data integration and meta-analysis","volume":"6","author":"Shim","year":"2021","journal-title":"Korea J Big Data"},{"key":"10.1016\/j.eururo.2023.10.012_b0090","unstructured":"Rohatgi A. WebPlotDigitizer: version 4.6. 2022. https:\/\/automeris.io\/WebPlotDigitizer\/citation.html."},{"key":"10.1016\/j.eururo.2023.10.012_b0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eururo.2023.10.012_b0100","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.10.012_b0105","doi-asserted-by":"crossref","first-page":"I4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.10.012_b0110","doi-asserted-by":"crossref","first-page":"e2019007","DOI":"10.4178\/epih.e2019007","article-title":"Diagnostic test accuracy: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.eururo.2023.10.012_b0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.urolonc.2011.02.023","article-title":"Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer","volume":"31","author":"Muacevic","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fonc.2012.00215","article-title":"Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer","volume":"2","author":"Ahmed","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2016.10.044","article-title":"A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer","volume":"102","author":"O\u2019Shaughnessy","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.10.012_b0135","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.10.012_b0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijrobp.2018.09.001","article-title":"Prospective immunophenotyping of CD8+ T cells and associated clinical outcomes of patients with oligometastatic prostate cancer treated with metastasis-directed SBRT","volume":"103","author":"Evans","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.10.012_b0145","first-page":"3119","article-title":"Image-guided stereotactic body radiotherapy in metastatic prostate cancer","volume":"38","author":"Pasqualetti","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2023.10.012_b0150","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography","volume":"1","author":"Kneebone","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ijc.32509","article-title":"Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial","volume":"146","author":"Bowden","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2023.10.012_b0160","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.10.012_b0165","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1158\/1078-0432.CCR-21-2510","article-title":"Phase II evaluation of stereotactic ablative radiotherapy (SABR) and immunity in 11C-choline-PET\/CT-identified oligometastatic castration-resistant prostate cancer","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2023.10.012_b0170","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s11547-021-01352-w","article-title":"Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes","volume":"126","author":"Mazzola","year":"2021","journal-title":"Radiol Med"},{"key":"10.1016\/j.eururo.2023.10.012_b0175","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ijrobp.2022.06.085","article-title":"Long-term outcomes of patients on a phase II prospective trial of oligometastatic hormone-sensitive prostate cancer treated with androgen deprivation and external beam radiation","volume":"114","author":"Hao","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.10.012_b0180","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ijrobp.2022.05.023","article-title":"Definitive local consolidative therapy for oligometastatic solid tumors: results from the lead-in phase of the randomized basket trial EXTEND","volume":"114","author":"Sherry","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.10.012_b0185","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2022.06.080","article-title":"Extended results and independent validation of a phase 2 trial of metastasis-directed therapy for molecularly defined oligometastatic prostate cancer","volume":"114","author":"Glicksman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.10.012_b0190","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.10.012_b0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euo.2021.10.002","article-title":"Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive oligometastatic prostate cancer: the OLI-P phase 2 clinical trial","volume":"5","author":"H\u00f6lscher","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0200","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s12094-021-02764-w","article-title":"Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis","volume":"24","author":"Deodato","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-022-01662-7","article-title":"Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer","volume":"39","author":"Reyes","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0210","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0215","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0220","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.euo.2022.02.002","volume":"5","author":"Pan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0225","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0230","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/cancers14092073","article-title":"Local control after locally ablative, image-guided radiotherapy of oligometastases identified by gallium-68-PSMA-positron emission tomography in castration-sensitive prostate cancer patients (OLI-P)","volume":"14","author":"H\u00f6lscher","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2023.10.012_b0235","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2018.12.020","article-title":"Early toxicity of a phase 2 trial of combined salvage radiation therapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07)","volume":"103","author":"Vaugier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.10.012_b0240","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.10.012_b0245","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.euo.2022.09.007","article-title":"Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasis-directed treatment in oligometastatic genitourinary cancers","volume":"6","author":"Huynh","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0250","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.10.012_b0255","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.10.012_b0260","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2023.10.012_b0265","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","article-title":"The Will Rogers phenomenon\u2014stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer","volume":"312","author":"Feinstein","year":"2010","journal-title":"N Engl J Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823032098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823032098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:14:24Z","timestamp":1759583664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823032098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0302283823032098"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.10.012","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}